Anaplastic Thyroid Carcinoma (ATC)

Anaplastic thyroid carcinoma (ATC) is a rare but extraordinarily aggressive undifferentiated malignancy of the thyroid gland, accounting for 1-2% of thyroid cancers but causing 14-50% of thyroid cancer deaths due to its dismal prognosis. Histopathologically characterized by complete loss of thyroid cell differentiation, sarcomatoid, giant cell, or squamoid morphology, high mitotic activity, vascular invasion, extensive necrosis, with TTF-1 and thyroglobulin negativity (loss of differentiation markers), Ki-67 typically >30%. Often arises through dedifferentiation from preexisting differentiated thyroid cancer (papillary or follicular) over years to decades, supported by frequent presence of differentiated thyroid cancer foci adjacent to anaplastic component (50-80%).

Molecular pathogenesis: most common mutations include BRAF V600E (~25-50%), TERT promoter (>70%, frequently coexisting with BRAF), TP53 (40-70%), RAS family (HRAS, KRAS, NRAS), PIK3CA, EIF1AX, ALK fusions (rare), NTRK fusions (rare). Stage IV by AJCC 8th edition is the only possible stage at presentation (no I, II, III): IVA (intrathyroidal disease, <1% of cases), IVB (gross extrathyroidal extension or regional nodes, ~40%), IVC (distant metastases — most common, ~50%). Common metastatic sites: lung (50-80%), bones, brain, soft tissues. Risk factors: older age (mean 65-70 years), female sex (slight predominance), preexisting thyroid disease (multinodular goiter, differentiated thyroid cancer history), iodine deficiency in some areas, prior radiation exposure (controversial).

Clinical presentation: rapidly enlarging neck mass over weeks to few months (in contrast to slow growth of differentiated thyroid cancer), compressive symptoms (dysphagia, dyspnea, stridor, hoarseness from recurrent laryngeal nerve invasion, vena cava obstruction syndrome), pain, hard fixed mass on examination, cervical lymphadenopathy, often with distant metastases at presentation (cough, hemoptysis from lung mets, bone pain, neurological symptoms from brain mets), constitutional symptoms (weight loss, fever, fatigue), occasionally hyperthyroidism from rapid hormone release. Diagnosis is by tissue biopsy (FNA may be inadequate, often requires core needle or open biopsy with extensive immunohistochemistry to confirm thyroid origin and exclude metastatic disease), pathology with immunohistochemistry (TTF-1 negative or focal, thyroglobulin negative, PAX-8 may be positive, cytokeratin variable, vimentin positive, p53 mutated, BRAF V600E IHC), MOLECULAR TESTING (BRAF V600E, NTRK, ALK, RET, mismatch repair, TMB) — URGENT and ESSENTIAL for treatment selection, neck/chest CT, neck ultrasound, PET-CT for staging, MRI brain/spine if symptoms, laryngoscopy for vocal cord assessment.

Treatment: requires URGENT multidisciplinary care given rapid disease progression. Multimodal therapy: surgery (R0 resection if feasible — total thyroidectomy with central and lateral neck dissection, possibly tracheal resection — best outcomes if achievable in IVA/IVB), external beam radiotherapy (often hyperfractionated, 60-70 Gy), chemotherapy (doxorubicin, paclitaxel, cisplatin/doxorubicin/paclitaxel triplet), targeted therapy: dabrafenib + trametinib (BRAF V600E — significant improvement in survival, FDA-approved for ATC), pembrolizumab + dabrafenib + trametinib (in trials), larotrectinib/entrectinib for NTRK fusion+, selpercatinib for RET-altered, alectinib for ALK+, lenvatinib in selected, immunotherapy (pembrolizumab for MSI-H, TMB-high). Tracheostomy for airway compromise, percutaneous endoscopic gastrostomy for nutrition. Critical: rapid initiation of treatment, often within days of diagnosis. Multidisciplinary tumor board, palliative care integration from diagnosis. Despite improvements, median survival remains 3-6 months, 1-year survival 10-20%, 5-year survival <5%.